Barbanti Piero, Le Pera Domenica, Cruccu Giorgio
Headache & Pain Unit, Department of Neurological, Motor & Sensorial Sciences, IRCCS San Raffaele, Rome, Italy.
Expert Rev Neurother. 2007 Aug;7(8):927-34. doi: 10.1586/14737175.7.8.927.
Sumatriptan is the first serotonin (5-hydroxytryptamine 5-HT) receptor agonist specifically designed for the acute treatment of migraine. A new sumatriptan fast disintegrating/rapid release tablet (FDT/RRT) using RT technology has been developed to enhance tablet disintegration and dispersion in the stomach with the intention of speeding absorption and onset of effect, hence mitigating the effects on the gastrointestinal dysmotility that typically accompanies the attack. Sumatriptan FDT/RRT is bioequivalent to conventional tablets, although it provides slightly faster absorption during early post-dose interval. Clinical trials indicate that sumatriptan FDT/RRT is rapidly effective in terms of freedom from pain and return to normal activities, both with early and late treatment. The drug is well tolerated. In an oral formulation, which is the patients' preferred dosing route, sumatriptan FDT/RRT may therefore constitute an advance in the management of acute migraine attacks.
舒马曲坦是首个专门用于偏头痛急性治疗的5-羟色胺（5-羟色胺5-HT）受体激动剂。一种采用RT技术的新型舒马曲坦快速崩解/速释片（FDT/RRT）已被研发出来，以增强片剂在胃中的崩解和分散，旨在加快吸收和起效，从而减轻发作时通常伴随的胃肠道动力障碍的影响。舒马曲坦FDT/RRT与传统片剂具有生物等效性，尽管它在给药后的早期间隔期吸收略快。临床试验表明，无论是早期治疗还是晚期治疗，舒马曲坦FDT/RRT在缓解疼痛和恢复正常活动方面都能迅速起效。该药物耐受性良好。在患者偏爱的口服给药方式中，舒马曲坦FDT/RRT可能因此在急性偏头痛发作的治疗方面取得了进展。
